Digital rectal examination, serum prostatic specific antigen or transrectal ultrasonography: the best tool to guide the treatment of men with benign prostatic hyperplasia
- 1 January 2009
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Urology
- Vol. 19 (1), 44-48
- https://doi.org/10.1097/mou.0b013e32831743d0
Abstract
Benign prostatic hyperplasia can be considered a progressive disease, and identifying men with progressive disease could have a significant impact on the decision to choose the different therapeutic options. Numerous pieces of evidence demonstrate the impact of the prostate volume on the disease progression. It has been accepted that digital rectal examination, serum prostatic specific antigen and transrectal prostate ultrasound are the available tools for the prostate volume estimation. This review examines the updated information on these tools for their guidance in the benign prostatic hyperplasia management. Digital rectal examination is unreliable in assessing the prostate volume; however, it is still important to use it to rule out prostate cancer or neurological problems. Prostatic specific antigens should be recommended as a part of patient evaluation because of their impact on the prediction of disease progression. Transrectal prostate ultrasound may be the best tool in the estimation of the exact prostate size. Numerous pieces of evidence have clearly demonstrated the impact of the prostate volume on the disease progression. Digital rectal examination seems to be good at identifying very large prostate. Prostatic specific antigen is the best tool for predicting disease progression and guiding the therapeutic options. For surgical guidance, transrectal prostate ultrasound is the useful tool available for the exact prostate volume estimation.Keywords
This publication has 21 references indexed in Scilit:
- Serum Prostate-Specific Antigen as a Predictor of Prostate Volume in the Community: The Krimpen StudyEuropean Urology, 2007
- CAN A BASELINE PROSTATE SPECIFIC ANTIGEN LEVEL IDENTIFY MEN WHO WILL HAVE LOWER URINARY TRACT SYMPTOMS LATER IN LIFE?Journal of Urology, 2005
- Natural history and clinical predictors of clinical progression in benign prostatic hyperplasiaCurrent Opinion in Urology, 2005
- Validity of Digital Rectal Examination and Serum Prostate Specific Antigen in the Estimation of Prostate Volume in Community-Based Men Aged 50 to 78 Years: The Krimpen StudyEuropean Urology, 2004
- EAU 2004 Guidelines on Assessment, Therapy and Follow-Up of Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction (BPH Guidelines)European Urology, 2004
- SERUM PROSTATE SPECIFIC ANTIGEN IS A STRONG PREDICTOR OF FUTURE PROSTATE GROWTH IN MEN WITH BENIGN PROSTATIC HYPERPLASIAJournal of Urology, 2000
- Prostate Volume and Serum Prostate–Specific Antigen as Predictors of Acute Urinary RetentionEuropean Urology, 2000
- DIGITAL RECTAL EXAMINATION FOR DETECTING PROSTATE CANCER AT PROSTATE SPECIFIC ANTIGEN LEVELS OF 4 NG./ML. OR LESSJournal of Urology, 1999
- The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic HyperplasiaThe New England Journal of Medicine, 1998
- Natural History of Prostatism: Risk Factors for Acute Urinary RetentionJournal of Urology, 1997